COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic

Incidence of Ventilator-associated Lower Respiratory Tract Infections Among Patients With SARS-CoV-2 Infection Throughout the First and the Second Wave of the Pandemic: a European Comparative Cohort Study

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05256511

Acronym

CoVAPid2

Enrollment

Registered

2022-02-25

Start date

2021-11-15

Completion date

2023-12-01

Last updated

2026-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe COVID-19

Keywords

SARS-CoV-2, ventilator-associated tracheobronchitis, ventilator-associated pneumonia, bacterial co-infection, COVID-associated pulmonary aspergillosis

Brief summary

Multicenter observational retrospective cohort study aiming at comparing the incidence of ventilator-associated lower respiratory tract infections between COVID-19 patients from the first and the second wave of the pandemic.

Detailed description

CoVAPid2 is a multicenter retrospective observational cohort study aiming at comparing the incidence of ventilator-associated lower respiratory tract infections between COVID-19 patients from the first and the second wave of the pandemic. Patients with confirmed SARS-CoV-2 community-acquired pneumonia and receiving invasive mechanical ventilation for more than 48h in the participating ICUs from the start of COVID pandemic are eligible for this study. Consecutive patients will be included from the beginning of the first wave (starting on 01-01-2020, data already collected in the CoVAPid1 study) and the second wave (starting on 10-01-2020). 10-20 patients per wave will be included in each center. VAT and VAP are defined using clinical, radiological and quantitative microbiological criteria.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Major (18 years and older) * Admitted to the ICU * Intubated and mechanically ventilated for more than 48 hours * With a confirmed community-acquired SARS-CoV2 pneumonia

Exclusion criteria

* Refusal to participate * Lack of social security coverage

Design outcomes

Primary

Measure	Time frame
Cumulative incidence of ventilator-associated lower respiratory tract infection (ventilator-associated pneumonia and ventilator associated tracheobronchitis)	from day 3 of mechanical ventilation to extubation or day 28 post-intubation

Secondary

Measure	Time frame
Cumulative incidence of ventilator-associated tracheobronchitis	from day 3 of mechanical ventilation to extubation or day 28 post-intubation
Cumulative incidence of ventilator-associated pneumonia	from day 3 of mechanical ventilation to extubation or day 28 post-intubation
Prevalence of early bacterial coinfection	from day 0 to day 2 of mechanical ventilation
Cumulative incidence of COVID-associated pulmonary aspergillosis	from day 3 of mechanical ventilation to extubation or day 28 post-intubation
ICU mortality	at day 28
Mortality	at day 28
Duration of mechanical ventilation (number of days under mechanical ventilation)	from the start of mechanical ventilation to extubation or day 28 after intubation
Duration of ICU stay (number of days in the ICU)	from the ICU admission to discharge or day 28 after admission

Countries

France

Contacts

PRINCIPAL_INVESTIGATORSaad NSEIR, MD,PhD

University Hospital, Lille

Outcome results